Search

EHA-AHK joint membership

How you can save money by becoming a joint member of EHA and the Asociacioni i Hematologëve të Kosovës. We've joined forces with the Asociacioni i Hematologëve të Kosovës (AHK) to offer a special joint membership deal.

EHA-MHTT joint membership

Save money and time by becoming a joint member of EHA and the Magyar Hematológiai és Transzfuziológiai Társaság. We've joined forces with the Magyar Hematológiai és Transzfuziológiai Társaság (MHTT) to offer a special joint membership deal.

EHA-SFH joint membership

Save money and time by becoming a joint member of EHA and the Société Française d’Hématologie. We've joined forces with the Société Française d’Hématologie (SFH) to offer a special joint membership deal.

EHA-SPH joint membership

Save money and time by becoming a joint member of EHA and the Sociedade Portuguesa de Hematologia. We've joined forces with the Sociedade Portuguesa de Hematologia (SPH) to offer a special joint membership deal.

EHA-SRH joint membership

Save money and time by becoming a joint member of EHA and the Societatea Română de Hematologie. We've joined forces with the Societatea Română de Hematologie (SRH) to offer a special joint membership deal.

EHA-THD joint membership

Save money and time by becoming a joint member of EHA and the Türk Hematoloji Derneği. We've joined forces with the Türk Hematoloji Derneği (THD) to offer a special joint membership deal.

Novel basis for chemoresistance in AML: DNMT3A R882 mutations promote chemoresistance and residual disease through impaired DNA damage sensing

Jun 12 2015 Posted in Press releases

Although most acute myeloid leukemia (AML) patients initially respond to chemotherapy, the majority subsequently relapses and succumbs to refractory disease. Residual leukemic cells that survived chemotherapy may persist over time and later cause the disease to come back.